This follow-up study is designed to evaluate the long-term safety and effectiveness of a treatment called anti-CD19 CAR-T cell therapy in adults with certain B-cell blood cancers. These cancers include types that have returned after treatment or have not responded to other therapies. CAR-T cell therapy involves using a patient's own immune cells, which are modified in a lab to specifically target and destroy cancer cells with a marker called CD19. The study will look at how well patients tolerate this treatment over time, as well as its ability to keep cancer in remission or reduce its severity.
Patients who have previously received CAR-T therapy in an earlier clinical trial and meet specific criteria can participate in this study. The research will include regular follow-up visits over approximately 11 months to monitor for side effects, assess cancer response, and track the activity of CAR-T cells in the body. This study does not involve additional treatments but focuses on understanding the long-term outcomes of CAR-T therapy to provide better care for patients in the future.
Successful completion of the HemC101-01-01 study procedures.
Negative pregnancy test for women of reproductive potential.
Uncontrolled life-threatening infection. A urinary tract infection is acceptable. Patients who received intravenous antibiotics before IMP administration or in whom intravenous antibiotics have not been discontinued 7 days before inclusion in the study. Prophylactic use of antibiotics, antiviral, or antifungal drugs is allowed.
The use of therapeutic interventions prohibited by the protocol (glucocorticosteroids, allogeneic cell therapy, GVHD therapy, chemotherapy, alemtuzumab, clofarabine, cladribine, and biologics derived from mouse materials).
Non-adherence to HemC101-01-01 study procedures that, in the investigator's opinion, put the patient at risk if they participate in the study and may significantly bias the assessment of study results.
Any clinically relevant data that, in the investigator's opinion, affects the patient's ability to enter the study and puts the patient at risk.
Patients who have received the IMP in the HemC101-01-01 study and completed it per protocol
Cohort
Prospective
Not listed
1. Incidence of Treatment-Emergent Adverse Events [Safety]
Frequency of any adverse events (AEs) reported during the study period and AE characterization (severity, seriousness, etc.)
ORR [Efficacy]
Overall response rate (ORR) defined as the proportion of subjects with complete response (CR) or partial response (PR)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
